Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 4/20 | 0.41 |
| ▸ | IL1B | P01584 | 3/20 | 0.41 |
| ▸ | CASR | P41180 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 7/20 | 0.37 |
| ▸ | CNR1 | P21554 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CMA1 | P23946 | 2/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1275921 | 0.87 | CHRM1 (0.45) | P2RX7IL1BCNR2CNR1CHRM1 | |
| SCHEMBL2037949 | 0.79 | P2RX7 (0.62) | P2RX7IL1BCNR2CNR1 | |
| SCHEMBL6871857 | 0.78 | CHRM1 (0.41) | P2RX7IL1BCNR2CNR1MAPT | |
| SCHEMBL6869518 | 0.77 | P2RX7 (0.42) | P2RX7IL1B | |
| SCHEMBL6870062 | 0.77 | P2RX7 (0.41) | P2RX7IL1BCNR2CNR1CHRM1 | |
| SCHEMBL2036074 | 0.76 | P2RX7 (0.47) | P2RX7IL1BCNR2CNR1MAPT | |
| SCHEMBL1988580 | 0.76 | CHRM1 (0.43) | P2RX7IL1BCNR2CNR1MAPT | |
| SCHEMBL23809515 | 0.75 | ATM (0.39) | P2RX7CASRCNR2CNR1MAPT | |
| SCHEMBL2033959 | 0.75 | P2RX7 (0.42) | P2RX7IL1B | |
| SCHEMBL1275017 | 0.74 | CHRM1 (0.53) | P2RX7IL1BCNR2CNR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2480232-B1 | DISUBSTITUTED ]4-(5-AMINOMETHYL-PHENYL)-PIPERIDIN-1-YL]-1H-INDOL-3-YL]-METHANONES | SANOFI SA (FR) | 2013-10-02 | — | — | EP | disclosed |
| EP-2480232-A1 | DISUBSTITUTED ]4-(5-AMINOMETHYL-PHENYL)-PIPERIDIN-1-YL]-1H-INDOL-3-YL]-METHANONES | SANOFI (FR) | 2012-08-01 | — | — | EP | disclosed |
| US-20120142735-A1 | DISUBSTITUTED [4-(5-AMINOMETHYL-PHENYL)-PIPERIDIN-1-YL]- 1H-INDOL-3-YL]-METHANONES | SANOFI (FR) | 2012-06-07 | — | — | US | disclosed |
| WO-2011022449-A1 | DISUBSTITUTED [4-(5-AMINOMETHYL-PHENYL)-PIPERIDIN-1-YL]-1H-INDOL-3-YL]-METHANONES | SANOFI-AVENTIS (FR) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142735-A1 | DISUBSTITUTED [4-(5-AMINOMETHYL-PHENYL)-PIPERIDIN-1-YL]- 1H-INDOL-3-YL]-METHANONES | CMA1, TPSB2, TPSAB1 | P2RX7 686/4885IL1B 1418/4885CASR 4279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.